POS0935 HIGHER 5-YEAR SURVIVAL OF CERTOLIZUMAB PEGOL IN YOUNG WOMEN WITH AXIAL SPONDYLOARTHRITIS. BIOBADASER DATA
Authors: M. Moreno, C. Sánchez-Piedra, V. Jovani, R. Cáliz Cáliz, Y. Perez-Vera, V. Emperiale, F. Sanchez-Alonso, M. Pombo, M. Llop Vilaltella, J. Calvet
Journal: Annals of the Rheumatic Diseases (2022)

Background Certolizumab pegol (CZP) in women of childbearing age with rheumatoid arthritis has a more favorable response, suggesting a possible distinctive effect in this group 1,2 . Objectives To evaluate the retention rate of CZP compared to other anti-TNFs and anti-IL17A in patients affected by axSpA, grouped according to gender and age Methods Cross-sectional study within the BIOBADASER registry. Patients older than 17 years old, with axSpA receiving anti-TNFs or anti-IL-17A were selected. Mean and standard deviations of ASDAS-CRP and BASDAI were performed at baseline, 1 st and 2 nd year of treatment. Patients were classified according to treatment into groups 1) CZP, 2) anti-TNF, and 3) anti-IL17A, and according to sex and age in the following groups: 1) women between 18 and 45 years old (young), 2) women over 45 years old (old), 3) men. Results Groups and gender distribution, treatment prescription, ASDAS-CRP and BASDAI values according to therapeutic line and demographical characteristics are shown in Table 1. Overall, young women treated with CZP showed remission or low activity during follow-up, compared to low activity for the rest of the molecules. Table 1. Efficacy data (BASDAI and ASDAS-CRP values) Index First line Second or subsequent lines All lines Baseline 1 year 2 or more Baseline 1 year 2 or more Baseline 1 year 2 or more Anti-TNF Female &lt;45 n=240 BASDAI 5.6 (2.3) 3.3 (2.1) 3.2 (2.0) 5.4 (2.5) 3.7 (2.3) 3.5 (2.2) 5.5(2.4) 3.5 (2.2) 3.3 (2.1) ASDAS-CRP 3.7 (1.2) 2.0 (0.9) 2.1 (0.9) 3.2 (2.0) 1.9 (1.0) 1.9 (1.1) 3.4 (1.7) 1.9 (1.0) 2.0 (1.0) Female &gt;45 n=367 BASDAI 6.0 (1.9) - 4.2 (2.6) 5.7 (2.3) - - 5.8 (2.2) - 4.2 (2.6) ASDAS-CRP 3.9 (0.9) - 1.8 (0.7) 3.3 (1.2) - - 3.6 (1.1) - 1.8 (0.7) Male n=1252 BASDAI 5.4 (2.1) 3.1 (2.1) 2.9 (1.9) 5.2 (2.4) 3.8 (2.5) 3.3 (2.3) 5.3 (2.3) 3.4 (2.3) 3.1 (2.1) ASDAS-CRP 3.3 (1.3) 1.9 (0.9) 1.8 (0.9) 3.0 (1.3) 2.0 (1.1) 2.2 (1.1) 3.2 (1.3) 1.9 (1.0) 1.9 (1.0) CZP Female &lt;45 n=35 BASDAI 5.5 (1.6) 3.0 (1.7) 1.3 (1.0) 5.2 (2.6) 3.9 (3.1) 2.9 (2.2) 5.3 (2.2) 3.5 (2.6) 2.2 (1.9) ASDAS-CRP 3.3 (0.5) 1.2 (0.5) 1.3 (1.1) 2.6 (1.1) 2.2 (1.2) 1.9 (0.7) 2.9 (0.9) 1.8 (1.1) 1.7 (0.8) Female &gt;45 n=25 BASDAI 6.7 (1.6) - - 6.4 (1.8) - - 6.4 (1.8) - ASDAS-CRP - - - 3.5 (1.1) - - 3.5 (1.1) - Male n=86 BASDAI 5.6 (2.3) 3.3 (2.0) 1.9 (2.0) 5.3 (2.4) 5.8 (1.8) 3.1 (2.7) 5.4 (2.3) 4.5 (2.3) 1.4 (2.3) ASDAS-CRP 2.4 (1.4) 2.2 (2.0) 1.5 (0.6) 3.1 (0.8) 2.8 (1.4) 2.1 (1.8) 2.8 (1.1) 2.4 (1.8) 1.7 (1.2) Anti-IL17A Female &lt;45 n=36 BASDAI 6.0 (1.4) 4.2 (2.0) 3.8 (1.7) 6.8 (2.2) 4.8 (2.3) 4.9 (2.6) 6.5 (1.9) 4.5 (2.1) 4.4 (2.2) ASDAS-CRP 3.6 (0.89) 1.8 (0.7) 1.6 (0.7) 3.3 (0.8) 2.0 (1.1) 1.8 (0.8) 3.4 (0.8) 1.9 (0.9) 1.7 (0.7) Female &gt;45 n=57 BASDAI 6.2 (1.8) - - 6.3 (1.8) - - 6.3 (1.8) ASDAS-CRP 3.7 (1.2) - - 3.8 (2.0) - - 3.8 (1.8) Male n=205 BASDAI 5.5 (2.2) 2.9 (2.3) 3.7 (2.5) 5.8 (2.3) 4.3 (2.2) 3.6 (2.4) 5.7 (2.3) 3.8 (2.3) 3.6 (2.4) ASDAS-CRP 3.2 (0.9) 1.6 (1.0) 1.9 (0.8) 3.4 (1.2) 2.5 (1.0) 2.5 (1.0) 3.4 (1.1) 2.1 (1.1) 2.3 (1.0) A greater survival of CZP compared to other treatment groups was observed in young women. This difference was observed since the first year of treatment (71,4 (64.2-77.4) all antiTNF, 84.4 (66.4-93.2) CZP, 72.2 (53.2-84.5) antiIL17) and the magnitude was maintained during the first 5 years of follow-up (Figure 1). In older women, a higher retention rate was observed for both CZP and anti-IL17A compared to anti-TNFs (71.6 (65.4-76.8) in all antiTNF, 78.1 (54.9-90.3) in CZP, 75.3 (61.3-84.9) in antiIL17). In males there were no long-term differences (79.2(76.3-81.8) all antiTNF, 73.0 (62.0-81.4) CZP, 64.6 (57.3-71.0) antiIL17) Figure 1. Five years retention rate (first line treatment) Focussed on first line treatment, the differences were greater in young women. The second and subsequent lines showed the same trends with a lesser extend. Globally, we do not observe these differences in men. Conclusion These data suggest a possible specific effect of Certolizumab Pegol in women with axial spondyloarthritis, especially in young women and when used as first line treatment. References [1]Favalli E, et al. FRI0114. ARD 2018. [2]Favalli EG, et al. FRI0042. ARD 2019 Acknowledgements We would like to thank all members who participated in the BIOBADASER project. Disclosure of Interests None declared